Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Teresa K. Chen, Aditya L. Surapaneni, Michelle M. Estrella, Lawrence J. Appel, Wassim Obeid, Chirag R. Parikh, Mary R. Rooney, Eugene P. Rhee, Insa M. Schmidt, Sushrut S. Waikar, Morgan E. Grams
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
10.1038/s41581-022-00621-9 · 2022
Inflammation and progression of CKD: the CRIC Study
10.2215/cjn.13121215 · 2016
Plasma biomarkers of tubular injury and inflammation are associated with CKD progression in children
10.1681/asn.2019070723 · 2020
Associations of plasma biomarkers of inflammation, fibrosis, and kidney tubular injury with progression of diabetic kidney disease: a cohort study
10.1053/j.ajkd.2021.09.018 · 2022
Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study
10.1093/eurjpc/zwad197 · 2023
Inflammation in heart failure: JACC state-of-the-art review
10.1016/j.jacc.2020.01.014 · 2020
The immunology of atherosclerosis
10.1038/nrneph.2017.51 · 2017
Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients
10.1681/asn.v13suppl_1s28 · 2002
Biomarkers of immune activation and incident kidney failure with replacement therapy: findings from the African American Study of Kidney Disease and Hypertension
10.1053/j.ajkd.2020.11.014 · 2021
Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality
10.1093/ndt/gfaa260 · 2021
Longitudinal TNFR1 and TNFR2 and kidney outcomes: results from AASK and VA NEPHRON-D
10.1681/asn.2021060735 · 2022
Associations of baseline and longitudinal serum uromodulin with kidney failure and mortality: results from the African American Study of Kidney Disease and Hypertension (AASK) trial
10.1053/j.ajkd.2023.05.017 · 2024
Comparison of aptamer-based and antibody-based assays for protein quantification in chronic kidney disease
10.2215/cjn.11700921 · 2022
Proteins associated with risk of kidney function decline in the general population
10.1681/asn.2020111607 · 2021
Multiple loci associated with indices of renal function and chronic kidney disease
10.1038/ng.377 · 2009
The associations of plasma biomarkers of inflammation with histopathologic lesions, kidney disease progression, and mortality-the Boston Kidney Biopsy Cohort study
10.1016/j.ekir.2020.12.025 · 2021
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
10.1001/jama.288.19.2421 · 2002
Intensive blood-pressure control in hypertensive chronic kidney disease
10.1056/nejmoa0910975 · 2010
The Atherosclerosis Risk in Communities (ARIC) study: design and objectives
10.1093/oxfordjournals.aje.a115184 · 1989
The prognostic value of histopathologic lesions in native kidney biopsy specimens: results from the Boston Kidney Biopsy Cohort study
10.1681/asn.2017121260 · 2018
NAT8 variants, N-acetylated amino acids, and progression of CKD
10.2215/cjn.08600520 · 2020
Serum and urine metabolites and kidney function
10.1681/asn.0000000000000403 · 2024
Circulating protein and metabolite correlates of histologically confirmed diabetic kidney disease
10.1016/j.xkme.2024.100920 · 2024
APOL1 kidney risk variants and proteomics
10.2215/cjn.14701121 · 2022
Analytical and biological variability of a commercial modified aptamer assay in plasma samples of patients with chronic kidney disease
10.1093/jalm/jfac145 · 2023
New creatinine- and cystatin C-based equations to estimate GFR without race
10.1056/nejmoa2102953 · 2021
Proteomics and incident kidney failure in individuals with CKD: the African American Study of Kidney Disease and Hypertension and the Boston Kidney Biopsy Cohort
10.1016/j.xkme.2024.100921 · 2024
The artificial sweetener erythritol and cardiovascular event risk
10.1038/s41591-023-02223-9 · 2023
Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study
10.1681/asn.2020040487 · 2021
Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study
10.1053/j.ajkd.2018.09.012 · 2019
Immune and inflammatory mechanisms in hypertension
10.1038/s41569-023-00964-1 · 2024
The role of interferon-gamma in cardiovascular disease: an update
10.1007/s00011-020-01382-6 · 2020
Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease
10.1161/circresaha.121.319077 · 2021
Interleukin-6 and cardiovascular events in healthy adults: MESA
10.1016/j.jacadv.2024.101063 · 2024
Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA)
10.1053/j.ajkd.2012.02.335 · 2012
Association of IL-8 with infarct size and clinical outcomes in patients with STEMI
10.1016/j.jacc.2018.04.053 · 2018
The relationship between IL-10 levels and cardiovascular events in patients with CKD
10.2215/cjn.08660813 · 2014
Serum uromodulin and mortality risk in patients undergoing coronary angiography
10.1681/asn.2016111162 · 2017
Association of serum uromodulin with mortality and cardiovascular disease in the elderly-the Cardiovascular Health Study
10.1093/ndt/gfz008 · 2020
Serum uromodulin: a biomarker of long-term kidney allograft failure
10.1159/000489095 · 2018
Novel findings from a metabolomics study of left ventricular diastolic function: the Bogalusa Heart Study
10.1161/jaha.119.015118 · doi-reference
Circulating metabolites improve the prediction of renal impairment in patients with type 2 diabetes
10.1136/bmjdrc-2023-003422 · doi-reference
Effects of dietary carbohydrate on 1,5-anhydroglucitol in a population without diabetes: results from the OmniCarb trial
10.1111/dme.13391 · doi-reference
Association of 1,5-anhydroglucitol with cardiovascular disease and mortality
10.2337/db15-0607 · doi-reference
Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial
10.1111/dom.13755 · doi-reference
Association of a biomarker of glucose peaks, 1,5-anhydroglucitol, with subclinical cardiovascular disease
10.2337/dc16-0840 · doi-reference
Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts
10.1056/nejmoa1800389 · doi-reference
Mediterranean diet, kidney function, and mortality in men with CKD
10.2215/cjn.01780213 · doi-reference
Mediterranean diet adherence and risk of all-cause mortality in women
10.1001/jamanetworkopen.2024.14322 · doi-reference
Adherence to healthy dietary patterns and risk of CKD progression and all-cause mortality: findings from the CRIC (Chronic Renal Insufficiency Cohort) study
10.1053/j.ajkd.2020.04.019 · doi-reference
DASH (Dietary Approaches to Stop Hypertension) diet and risk of subsequent kidney disease
10.1053/j.ajkd.2016.05.019 · doi-reference
A clinical trial of the effects of dietary patterns on blood pressure
10.1056/nejm199704173361601 · doi-reference
Adherence to the mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study
10.1161/circulationaha.107.710699 · doi-reference
Twelve-week Mediterranean diet intervention increases citrus bioflavonoid levels and reduces inflammation in people with type 2 diabetes mellitus
10.3390/nu13041133 · doi-reference
Identification of protein biomarkers of the Dietary Approaches to Stop Hypertension diet in randomized feeding studies and validation in an observational study
10.1161/jaha.122.028821 · doi-reference
Effects of the Dietary Approaches to Stop Hypertension diet on change in cardiac biomarkers over time: results from the DASH-Sodium trial
10.1161/jaha.122.026684 · doi-reference
Effects of diet and sodium reduction on cardiac injury, strain, and inflammation: the DASH-Sodium trial
10.1016/j.jacc.2021.03.320 · doi-reference
The association of serum carotenoids, tocopherols, and ascorbic acid with rapid kidney function decline: the Coronary Artery Risk Development in Young Adults (CARDIA) study
10.1053/j.jrn.2018.05.008 · doi-reference
Plasma tryptophan-kynurenine pathway metabolites and risk for progression to end-stage kidney disease in patients with type 2 diabetes
10.2337/dc23-1147 · doi-reference
IL8 and IL16 levels indicate serum and plasma quality
10.1515/cclm-2017-1047 · doi-reference
Metabolites associate with kidney function decline and incident chronic kidney disease in the general population
10.1093/ndt/gft217 · doi-reference
IDO expression by dendritic cells: tolerance and tryptophan catabolism
10.1038/nri1457 · doi-reference
Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells
10.1006/cyto.1999.0661 · doi-reference
Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced antichlamydial indoleamine dioxygenase activity independently
10.1089/107999000312306 · doi-reference
Synergistic transcriptional activation of indoleamine dioxygenase by IFN-γ and tumor necrosis factor-α
10.1089/107999003322277829 · doi-reference
Associations of urine epidermal growth factor with kidney and cardiovascular outcomes in individuals with CKD in SPRINT
10.1016/j.ekir.2024.08.004 · doi-reference
Urine epidermal growth factor and kidney function decline in middle-aged adults
10.1016/j.xkme.2024.100846 · doi-reference